<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01812486</url>
  </required_header>
  <id_info>
    <org_study_id>S50809</org_study_id>
    <nct_id>NCT01812486</nct_id>
  </id_info>
  <brief_title>Dose De-escalation to the Elective Nodal Sites in Head and Neck Cancer</brief_title>
  <official_title>Dose De-escalation to the Elective Nodal Sites, the Swallowing Apparatus and Neck Soft Tissues for Head and Neck Cancer: Multi-centre, Randomized Phase III Trial Using Image-guided Intensity-modulated Radiotherapy (IG-IMRT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized clinical trial was initiated to investigate whether a reduction of the dose to
      the elective nodal sites and the swallowing apparatus delivered by IMRT would result in a
      reduction of acute and late side effects without compromising tumor control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Study hypothesis

           Dose de-escalation in the elective nodal sites and off-target regions of the swallowing
           apparatus delivered by IMRT does reduce overall rate of late dysphagia and neck fibrosis
           comparing to the standard dose to the elective nodal sites.

        2. Primary endpoint

           To estimate the difference in overall rate of late dysphagia and neck fibrosis 1 year
           after the end of radiotherapy in patients receiving dose de-escalation to the elective
           nodal sites and off-target regions of the swallowing apparatus applying IMRT.

        3. Secondary endpoints

      Local, regional and distant control Recurrence and site of recurrence Overall, disease-free
      and disease-specific survival Acute toxicity Quality of life
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall rate of late dysphagia and neck fibrosis</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>locoregional control</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute dysphagia</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NID2Gy = 50 Gy Swallowing apparatus: standard dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental de escalated arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NID2Gy = 40 Gy Swallowing apparatus: Dmax ≤ 60 Gy at 1 cm Dmax ≤ 50 Gy at 1.5 cm from the GTV or PSTB edge</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>dose de escalation</intervention_name>
    <arm_group_label>Experimental de escalated arm</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>standard dose</intervention_name>
    <arm_group_label>control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        oral cavity, oropharynx, hypopharynx and larynx SCC Histolocervical lymph node metastases
        of unknown primary cancer Primary unresectable tumor and/or patients refused surgery Stage
        T2-4; T3-4 N0 Tany N1-3 for laryngeal cancer Karnofsky performance status ≥70% Age ≥ 18
        years old

        Exclusion Criteria:

        Treatment combined with brachytherapy Prior irradiation to the head and neck region History
        of prior malignancies, except for cured non-melanoma skin cancer, curatively treated
        in-situ carcinoma of the cervix or other cancer curatively treated and with no evidence of
        disease at least 5 years Distant metastases Pregnant or lactating women Patient unlikely to
        comply with the protocol, i.e. uncooperative attitude, inability to return for follow-up
        visits, and unlikely to complete the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospitals UZLeuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2013</study_first_submitted>
  <study_first_submitted_qc>March 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2013</study_first_posted>
  <last_update_submitted>March 15, 2013</last_update_submitted>
  <last_update_submitted_qc>March 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Dr. Sandra Nuyts</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

